

CLINICAL TRIAL REPORT
INTERNATIONAL APPROVAL FORM

TRIAL TITLE: A Multicenter, Double-Blind, Randomized, Controlled, Multiple Fixed-Dose and Dose Regimen Comparison of SEROQUEL™ (ICI 204,636) and Haloperidol in the Prevention of Psychotic Relapse in Outpatients with Chronic or Subchronic Schizophrenia


TRIAL NUMBER: 5077IL/0015

AUTHORS: Lisa Arvanitis, MD
Project Physician

Mark Scott, PhD
Project Biometrician


DATE NEEDED: ASAP

ROUTE/RETURN TO: J. Borak/Hanby-2



LISA ARVANITIS, MD
INTERNATIONAL PROJECT PHYSICIAN

4/23/96
DATE



MARK SCOTT, PhD
INTERNATIONAL PROJECT BIOMETRICIAN

4/23/96
DATE

SEROQUEL™

A Multicenter, Double-Blind, Randomized, Controlled, Multiple Fixed-Dose and Dose Regimen Comparison of SEROQUEL™ (ICI 204,636) and Haloperidol in the Prevention of Psychotic Relapse in Outpatients with Chronic or Subchronic Schizophrenia

Trial number: 5077IL/0015
First patient entered: 27 July 1993
Data cutoff date: 1 June 1995

The attached report is an accurate record of the trial conducted with SEROQUEL.

Alexander Miller, MD
University of Texas Health Science Center, Department of Psychiatry
7703 Floyd Curl Drive
San Antonio, TX 78284-7792

Alexander Miller, M.D.
Signature

June 12, 1996
Date

SEROQUEL is a trademark, the property of Zeneca Limited.

3.2 Withdrawals

Summary tables: disposition of randomized patients: withdrawals and reason for withdrawals; T6.1.1 and T6.1.2

Individual patient listings: time to patient withdrawal/relapse; G3

Statistical appendix: H3.1

Table 7 presents the disposition of all randomized patients and their reasons for withdrawal.

TABLE 7 Disposition of patients and reasons for withdrawal

	Treatment group			
	SEROQUEL			Haloperidol
	75 mg n (%)	300 mg n (%)	600 mg n (%)	n (%)
Patients randomized	85 (100)	88 (100)	87 (100)	41 (100)
Patients completed	7 (8)	11 (13)	14 (16)	13 (32)
Patients ongoing	6 (7)	3 (3)	7 (8)	1 (2)
Patients withdrawn	72 (85)	74 (84)	66 (76)	27 (66)
Reason for withdrawal				
Psychotic relapse	45 (63)	48 (65)	35 (53)	8 (30)
Psychotic relapse, criteria I	29 (64)	31 (65)	24 (69)	4 (50)
Psychotic relapse, criteria II	16 (36)	16 (33)	11 (31)	4 (50)
Psychotic relapse, neither criteria	0	1 (2)	0	0
Refused to continue, lost to follow-up	15 (21)	9 (12)	14 (21)	4 (15)
Adverse event/intercurrent illness	7 (10)	13 (18)	13 (20)	14 (52)
Protocol noncompliance	5 (7)	4 (5)	4 (6)	1 (4)

As seen in Table 7, the overall proportion of patients who completed the trial was low. There appeared to be an increase in the proportion of patients completing the trial as the SEROQUEL dose increased. A higher proportion of patients in the haloperidol group than in each of the SEROQUEL groups completed the trial.

The proportion of patients who withdrew due to psychotic relapse was similar in the SEROQUEL groups and greater than that in the haloperidol group. Of the withdrawals due to psychotic relapse, a greater proportion in each SEROQUEL group withdrew due to psychotic relapse Criteria I than Criteria II. In the haloperidol group, of the patients who withdrew due to psychotic relapse, the proportion who withdrew due to Criteria I was the same as that for Criteria II.

The proportion of patients who withdrew due to adverse events or intercurrent illnesses was lower for each SEROQUEL group (range 10 to 20%) compared with the haloperidol group (52%). Details of the adverse events leading to withdrawal in all treatment groups are given in Section 5.3.3.